Financebotresearch desk研究台

LDOS › analyze

LDOS · Analyze

ACCUMULATE Technology

Date: 2026-08-04 | Price: $130.60 (+8.8% on the print) | Market cap: $16.43B Prior file: analyze-2026-07-14.md at $118.36 · +10.3% in three weeks

Headline: every written break trigger was tested and cleared

The July file set three break triggers. The Q2 print tested all three head-on. This is the cleanest confirmation any name on the watchlist has produced this year.

Break trigger (set 2026-07-14) Q2 CY2026 result
FY26 guidance cut Revenue guide raised to $18.2–18.4B (from $18.0–18.4B); EPS and OCF guidance raised ✅ cleared
Book-to-bill <1.0× for 2 quarters Total 1.1×; Defense 2.2× in the quarter, 1.9× trailing twelve months ✅ cleared decisively
FCF margin rollback Q2-record OCF of ~$800M; paid off the remaining $300M of commercial paper ✅ cleared

Q2: revenue $4.6B, +7% YoY (a Q2 record), adjusted EBITDA margin 13.8%, non-GAAP EPS $3.26 vs $2.91 consensus, backlog $48.7B, gross leverage 2.5×.

The one number that needs care: EPS grew 1.6%, not 12%

Non-GAAP EPS was $3.26 against $3.21 a year ago — +1.6% YoY. The widely-quoted figure is the $0.35 beat versus consensus, which is a statement about analyst modelling, not about the business. Treat those as different facts.

The reason the quarter looks flat and the year does not is the VA Health headwind, which is dated, quantified and already inside guidance:

The VA has suspended incentive payments on the medical disability examination (MDE) business for the remainder of 2026. Management has absorbed it into the raised guide.

Strip Health out and the picture is the real one: the rest of Leidos is guided to ~+7% revenue and ~+19% adjusted EBITDA growth in 2026, led by defense tech, energy and cyber. Full-year guidance of $12.20–12.50 against FY2025's $11.14 is +9.5% to +12.2%. The quarter is a comp artifact; the year is not.

The genuine risk in this paragraph is the recompete, not the suspension. Leidos QTC must re-secure the MDE franchise. The platform it is defending — 15,000 providers, 90 clinics, 2.8 million exams annually — is not trivially replicable, and the VA's stated pivot toward quality and veteran experience favours the incumbent. But a loss here is the one identifiable event that breaks the thesis, and it is not scheduled.

Financial health — the three-year record is the strongest on the watchlist

Fiscal year 2022 2023 2024 2025 3yr CAGR
Revenue $14.40B $15.44B $16.66B $17.17B +6.1%
Operating income $1.13B $1.30B $1.81B $2.10B +23.0%
Operating margin 7.8% 8.4% 10.9% 12.2% +440bps
Net income $685M $199M $1.25B $1.45B +28.3%
Diluted EPS $4.96 $1.44 $9.22 $11.14 +30.9%
FCF $863M $980M $1.29B $1.62B +23.5%
Diluted shares 138.0M 138.0M 136.0M 130.0M −2.0%

Operating income rose 86% in three years on 19% revenue growth. Operating margin went 7.8% → 12.2%. This is the opposite of the pattern found in every other name analysed this week — here the incremental dollar of revenue arrives at a higher margin than the one before it.

FCF compounded 23.5%, and unlike the AI-capex cohort the cash is real: capex is $125M on $17.17B of revenue (0.7%), so OCF and FCF are nearly the same number. There is no capex cliff hiding under this business.

Capital allocation is disciplined and shareholder-friendly:

2022 2023 2024 2025
Buybacks $542M $246M $906M $944M
Dividends $199M $201M $208M $211M
Debt issued / (repaid) $380M / −$545M $1.74B / −$2.04B $0 / −$18M $997M / −$1.02B
Total debt $5.49B $5.20B $5.29B $5.24B

Debt is flat to slightly down over four years while $2.64B went to buybacks. Debt/assets 38.8%, gross leverage 2.5× and falling — the $300M commercial-paper paydown this quarter is on-trend, not a gesture. Shares 138.0M → 126.4M outstanding. The buyback is funded by cash flow, not by the balance sheet. (Contrast Gartner's 169%-of-FCF, debt-funded programme in the same sector folder.)

Dividend yield 1.49% at a 15% payout ratio — the smallest income contribution on the watchlist, but with more headroom than anything else on it.

✅ Diagnostic check: net margin 8% < operating margin 12%. No equity-mark distortion — [[pitfall-unrealized-equity-marks-break-headline-pe]] does not fire here. Every dollar of Leidos' reported earnings came from operations. After four names this week where that was not true, it is worth stating explicitly.

Moat

Leidos' advantage is incumbency inside classified and mission-critical government programmes, which is a genuinely different asset from commercial switching costs. The barriers are procedural: cleared personnel at scale, past-performance qualification, facility accreditation, and program-of-record positions that are re-competed on multi-year cycles rather than annually. A competitor cannot buy its way in within a budget cycle.

The stress test. The vector that actually threatens LDOS is not a rival prime — it is procurement reform: fixed-price conversion, insourcing, or the "software-first, primes-last" posture that has favoured newer defense-tech entrants. That pressure is real and it is why the whole services group trades at 10–12× while the hardware primes trade higher.

The Q2 evidence argues Leidos is on the right side of it: Defense book-to-bill 2.2× in the quarter and 1.9× trailing twelve months, on wins in munitions, unmanned surface vessels and space payloads — the three areas where budget growth is fastest and where the work is closer to product than to staff augmentation. A 1.9× ttm book-to-bill means the company booked nearly two dollars of future work for every dollar it recognized. Backlog $48.7B is 2.66× FY26 revenue.

Evergreen rating: 7/10. Not permanent — government services is a political sector and always will be — but the backlog gives 2–3 years of visibility that almost nothing else on the watchlist offers, and the mix is shifting toward the durable end.

Valuation

Method Input Result
Forward P/E $130.60 ÷ $12.35 (FY26 guide midpoint) 10.6×
Trailing P/E 11.95×
P/FCF $130.60 ÷ $12.50 FCF/share 10.4×
EV/EBITDA 8.9×
Graham IV √(22.5 × 11.14 × 39.85) $99.00
Bogle expected return 1.49% yield + ~10% EPS growth ~11.5% + multiple change
Consensus target $150.67 (+15.4%)

Graham returns $99.00 — below spot, as it will for any asset-light services company with $39.85 of book value. It is a floor indication, not a fair value, and it is the only model of the four that says this is not cheap.

Fair value: $148–173, central $161. That is 12–14× the FY26 guide midpoint. The multiple is deliberately unheroic — services businesses do not deserve a market multiple, and 14× is where the better-run peers (BAH, CACI) have historically topped out rather than a re-rating fantasy.

At $130.60 the stock is ~23% below central fair value even after today's +8.8%.

Verdict — 🟢 ACCUMULATE · conviction [7.5] → [8.0] ⬆️

Upgraded, and this one is earned by the written test rather than by the price.

The July file listed three conditions that would break the thesis. The print tested all three and cleared all three — the guide went up, book-to-bill came in at 1.1× total and 2.2× in Defense, and OCF set a Q2 record. When a name is gated on falsifiable conditions and the conditions come back clean, the rating moves. That is the same discipline that is holding Gartner at [6.0] today, applied in the other direction.

What the deeper look added beyond the print: operating margin 7.8% → 12.2% and FCF compounding 23.5% over three years, with debt flat and the buyback fully cash-funded. The July file had the thesis right and understated the quality of the underlying record.

Why not higher than [8.0]: the quarter's underlying EPS growth was +1.6%, the VA MDE recompete is an unscheduled binary on a real revenue line, and the name has now run +10.3% in three weeks — consistent with [[pattern-shortlist-runs-when-unexecuted]], which records shortlist names running 8–27% before they get bought. It is cheap, not free.

Zones: entry $115 → $115–135 — the stock is in the add zone at $130.60, at the upper end. Trim 14× fwd. Preferred over BAH; still do not need both.

A portfolio-specific passage was removed from the public build.

Sources